EP3450460A4 - Multi-specific binding conjugate, related pharmaceutical compositions and use - Google Patents
Multi-specific binding conjugate, related pharmaceutical compositions and use Download PDFInfo
- Publication number
- EP3450460A4 EP3450460A4 EP16900170.8A EP16900170A EP3450460A4 EP 3450460 A4 EP3450460 A4 EP 3450460A4 EP 16900170 A EP16900170 A EP 16900170A EP 3450460 A4 EP3450460 A4 EP 3450460A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical compositions
- specific binding
- related pharmaceutical
- binding conjugate
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23181122.5A EP4245775A3 (en) | 2016-04-29 | 2016-10-13 | Multi-specific binding conjugate, related pharmaceutical compositions and use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016080749 | 2016-04-29 | ||
PCT/CN2016/101984 WO2017185662A1 (en) | 2016-04-29 | 2016-10-13 | Multi-specific binding conjugate, related pharmaceutical compositions and use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23181122.5A Division EP4245775A3 (en) | 2016-04-29 | 2016-10-13 | Multi-specific binding conjugate, related pharmaceutical compositions and use |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3450460A1 EP3450460A1 (en) | 2019-03-06 |
EP3450460A4 true EP3450460A4 (en) | 2019-12-25 |
EP3450460C0 EP3450460C0 (en) | 2023-07-12 |
EP3450460B1 EP3450460B1 (en) | 2023-07-12 |
Family
ID=60161787
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23181122.5A Pending EP4245775A3 (en) | 2016-04-29 | 2016-10-13 | Multi-specific binding conjugate, related pharmaceutical compositions and use |
EP16900170.8A Active EP3450460B1 (en) | 2016-04-29 | 2016-10-13 | Multi-specific binding conjugate, related pharmaceutical compositions and use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23181122.5A Pending EP4245775A3 (en) | 2016-04-29 | 2016-10-13 | Multi-specific binding conjugate, related pharmaceutical compositions and use |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP4245775A3 (en) |
CN (1) | CN109195992A (en) |
WO (1) | WO2017185662A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11525009B2 (en) | 2016-06-22 | 2022-12-13 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Bispecific antibody and antibody conjugate for tumor therapy and use thereof |
WO2018058111A1 (en) * | 2016-09-26 | 2018-03-29 | The Brigham And Women's Hospital, Inc. | Regulators of b cell-mediated immunosuppression |
CN110382550A (en) * | 2017-01-24 | 2019-10-25 | 本康生物制药(深圳)有限公司 | Antibody coupling matter, relevant pharmaceutical composition and application |
WO2018166527A1 (en) * | 2017-03-17 | 2018-09-20 | 本康生物制药(深圳)有限公司 | Multispecific antibody, antibody conjugate and related pharmaceutical composition and use |
US12077586B2 (en) | 2018-09-19 | 2024-09-03 | LAVA Therapeutics N.V. | Bispecific antibodies for use in the treatment of hematological malignancies |
US20220185903A1 (en) * | 2019-03-04 | 2022-06-16 | Nantong Yichen Biopharma. Co. Ltd. | Novel bispecific binding molecule and drug conjugate thereof |
CN113125730B (en) * | 2019-12-31 | 2023-07-07 | 科美博阳诊断技术(上海)有限公司 | Homogeneous detection kit for interleukin 6 and application thereof |
CN113125732B (en) * | 2019-12-31 | 2023-08-08 | 科美博阳诊断技术(上海)有限公司 | Homogeneous detection kit for interleukin 6 and application thereof |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
CN114047336A (en) * | 2021-12-13 | 2022-02-15 | 大连医科大学 | Biomarker for assisting in diagnosing recurrent abortion and application thereof |
WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
WO2024100046A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104829730A (en) * | 2015-04-14 | 2015-08-12 | 苏静 | Bispecific antibody capable of combining immune cells to enhance tumor killing ability, preparation method and applications thereof |
WO2017219974A1 (en) * | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | Bispecific antibody and antibody conjugate for tumour therapy and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69030172T2 (en) | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
ES2565543T3 (en) * | 2005-01-24 | 2016-04-05 | Board Of Regents, The University Of Texas System | Fc fusion constructs to phosphatidylserine binding and its therapeutic use |
CN103936859A (en) * | 2005-03-03 | 2014-07-23 | 免疫医疗公司 | Humanized L243 antibodies |
CN101534865A (en) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
EP4083072A1 (en) * | 2008-10-06 | 2022-11-02 | Minerva Biotechnologies Corporation | Muc1* antibodies |
WO2013090293A1 (en) * | 2011-12-15 | 2013-06-20 | The University Of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
JP6571527B2 (en) * | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2016
- 2016-10-13 WO PCT/CN2016/101984 patent/WO2017185662A1/en active Application Filing
- 2016-10-13 EP EP23181122.5A patent/EP4245775A3/en active Pending
- 2016-10-13 EP EP16900170.8A patent/EP3450460B1/en active Active
- 2016-10-13 CN CN201680085024.9A patent/CN109195992A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104829730A (en) * | 2015-04-14 | 2015-08-12 | 苏静 | Bispecific antibody capable of combining immune cells to enhance tumor killing ability, preparation method and applications thereof |
WO2017219974A1 (en) * | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | Bispecific antibody and antibody conjugate for tumour therapy and use thereof |
Non-Patent Citations (3)
Title |
---|
GLORIUS P. ET AL: "The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells", LEUKEMIA, vol. 27, no. 1, 4 June 2012 (2012-06-04), pages 190 - 201, XP055268824 * |
KELLNER C. ET AL: "Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells", CANCER LETTERS, vol. 303, no. 2, 28 April 2011 (2011-04-28), pages 128 - 139, XP055311969 * |
SCHLENZKA J. ET AL.: "Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B-cell lymphoma", ANTI-CANCER DRUGS, vol. 15, October 2004 (2004-10-01), pages 915 - 919, XP002795673 * |
Also Published As
Publication number | Publication date |
---|---|
EP3450460C0 (en) | 2023-07-12 |
EP4245775A2 (en) | 2023-09-20 |
WO2017185662A1 (en) | 2017-11-02 |
EP4245775A3 (en) | 2023-11-15 |
EP3450460A1 (en) | 2019-03-06 |
EP3450460B1 (en) | 2023-07-12 |
CN109195992A (en) | 2019-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3450460A4 (en) | Multi-specific binding conjugate, related pharmaceutical compositions and use | |
EP3315608A4 (en) | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof | |
EP3436482A4 (en) | Antibodies, pharmaceutical compositions and methods | |
EP3480211A4 (en) | Hanp-fc-containing molecular conjugate | |
EP3129048A4 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
EP3641771A4 (en) | Pharmaceutical compositions | |
EP3513809A4 (en) | Medicinal composition | |
EP3359193A4 (en) | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof | |
EP3434285A4 (en) | Pharmaceutical composition and use thereof | |
EP3560517A4 (en) | Aptamer-drug conjugate and use thereof | |
EP3399978A4 (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses | |
AU2018302170A1 (en) | Pharmaceutical compositions comprising entrectinib | |
EP3381925A4 (en) | Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof | |
EP3581183A4 (en) | Tumor-treating pharmaceutical composition | |
IL252397A0 (en) | Pharmaceutical composition, preparation and uses thereof | |
IL290114A (en) | Pharmaceutical composition, preparation and uses thereof | |
EP3583943A4 (en) | Pharmaceutical composition | |
EP3402470A4 (en) | Stable pharmaceutical composition | |
LT3229843T (en) | Pharmaceutical composition, preparation and uses thereof | |
EP3524250A4 (en) | Pharmaceutical composition | |
EP3720844A4 (en) | Drug compositions | |
EP3302483A4 (en) | Pharmaceutical compositions and use thereof | |
EP3719010A4 (en) | Aromatic compound, pharmaceutical composition thereof and use thereof | |
EP3646867A4 (en) | Pharmaceutical composition | |
EP3300474A4 (en) | Betacryptoxanthin compositions, processes for preparation and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181025 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: YU, HAOYANG Inventor name: LI, ZHENGCHENG Inventor name: SU, JING |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191126 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/44 20060101ALI20191119BHEP Ipc: C07K 16/30 20060101ALI20191119BHEP Ipc: C07K 16/28 20060101ALI20191119BHEP Ipc: A61P 35/00 20060101ALI20191119BHEP Ipc: C07K 16/46 20060101AFI20191119BHEP Ipc: A61P 35/02 20060101ALI20191119BHEP Ipc: C07K 19/00 20060101ALI20191119BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40002482 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200702 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20220704 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230206 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016081071 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20230811 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230818 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 8 Effective date: 20230905 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231012 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231112 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231013 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016081071 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230712 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20240415 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20231013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231013 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031 |